Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
- Submitting institution
-
The University of Leicester
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 70
- Type
- D - Journal article
- DOI
-
10.1016/S0140-6736(17)30550-0
- Title of journal
- The Lancet
- Article number
- .
- First page
- 2117
- Volume
- 389
- Issue
- 10084
- ISSN
- 0140-6736
- Open access status
- Compliant
- Month of publication
- March
- Year of publication
- 2017
- URL
-
https://www.sciencedirect.com/science/article/pii/S0140673617305500?via%3Dihub
- Supplementary information
-
https://doi.org/10.1016/S0140-6736(17)30550-0
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
16
- Research group(s)
-
A - Cardiovascular
- Citation count
- 91
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
